Controlled Anti-platelet medical therapy based on rapid CYP2C19 gene evaluation in Acute myocardial infarction

Controlled Anti-platelet medical therapy based on rapid CYP2C19 gene evaluation in Acute myocardial infarction - CALDERA-GENE STUDY

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008151

Enrollment

100

Registered

2012-06-12

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Non-carriers of CYP2C19 reduced function allele with standard dual anti-platelet therapy(asprin 100mg + clopidogrel 75mg) Carriers of CYP2C19 reduced function allele with standard dual anti-platelet t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with ST elevation myocardial infarction and non ST elevation myocrdial ingarction who underwent emergent percutaneous coronary intervention.

Exclusion criteria

Exclusion criteria: We exclude patients with deep vein thrombosis, cerebral infarction, atrial fibrillation, collagen disease ,disseminated intravascular coagulation, sepsis, severe infection and malignant diseases. We exclude patients who were treated with warfarin, steroids, thrombolytic agents, ticlopidine, sarpogrelate or cilostazol. We exclude patients with severe liver or renal dysfunction. We exclude patients who need mechanical cardio-plumonary supports such as intraaortic balloon pumping(IABP) or percutaneous cardiopulmonary support(PCPS).

Design outcomes

Primary

Measure	Time frame
1.The frequency of CYP2C19 2, 3, and *17 polymorphism in acute myocardial infarction. 2.Difference of several change in the residual platelet aggregation and the biomarkers for blood coagulation and cardiac biomarkers.	—

Secondary

Measure	Time frame
Composite cardiovascular events(cardiac death, fatal and non fatal stroke, non-fatal myocardial infarction, hospitalization for cardiovascular event, percutaneous coronary intervention or coronary artery bypass graft, hospitalization for heart failure, deep vein thrombosis, pulmonary thromboembolism, hospitalization for peripheral arterial disease, hemorrhagic complication)	—

Countries

Japan

Contacts

Public ContactKoichi Kaikita

Graduate School of Medical Sciences, Kumamoto University Cardiovascular medicine

kaikitak@kumamoto-u.ac.jp096-373-5175

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026